Want to see NUS full AI Analyst Report?
Nu Skin (NUS) AI Stock Analysis
Nu Skin
(NYSE:NUS)
Nu Skin's weak overall score of 43 is primarily driven by profound fundamental challenges, including years of persistent revenue decline, severe net losses, and massive non-cash impairment charges. Additionally, sluggish sales force recruitment and delays in expanding to high-potential markets like India compound top-line fragility. While the company's aggressive debt reduction and the growth of its Prysm iO device offer slight optimism, the stock remains trapped in a strong technical downtrend. Until the company can stabilize its legacy markets and convert its new product initiatives into sustainable free cash flow, risks heavily outweigh potential rewards.
Nu Skin Key Performance Indicators (KPIs)
Revenue by SegmentBreaks down sales across the company’s segments so you can see where growth is coming from and how diversified the business is. For Nu Skin, this reveals dependence on specific regions, product categories, or distributor channels, helps identify fast‑growing versus stagnant areas, and flags concentration or seasonal risks that could affect future top‑line momentum.
Nu Skin’s revenue mix has shifted: legacy consumer sales in Mainland China and the Americas have trended down, while Manufacturing and the Rhyz/RISE-related lines spiked in 2023–24—helping core gross margins and EPS in 2025—but Rhyz revenues pulled back in 2025 and China/Americas weakness persists, leaving top-line growth fragile. Management’s 2026 guidance is cautious and pins upside on nascent Prism IO device placements and India expansion; monetization and slower consumer adoption remain execution risks, so margin gains may outpace revenue recovery unless subscription conversion accelerates.
Nu Skin (NUS) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $226.35M
- Dividend Yield
- 5.16%
- Average Volume (3M)
- 528.09K
- Price to Earnings (P/E)
- -1.0
- Beta (1Y)
- 1.28
- Revenue Growth
- -15.44%
- EPS Growth
- -319.79%
- Country
- US
- Employees
- 2,800
- Sector
- Consumer Defensive
- Sector Strength
- 62
- Industry
- Household & Personal Products
Nu Skin Business Overview & Revenue Model
Company Description
Nu Skin Enterprises, Inc. (NUS) is a global enterprise dedicated to the creation and worldwide distribution of beauty and wellness solutions. The company's diverse product offerings encompass advanced skincare systems, such as the ageLOC Spa and ageL...
How the Company Makes Money
Nu Skin makes money primarily by selling its beauty and wellness products through a direct-selling (multi-level) distribution channel. The company generates revenue when products are purchased from Nu Skin by its independent salesforce (often referre...
Nu Skin Earnings Call Summary
The call presented a mixed picture: strong product momentum and engagement around Prysm iO, improved core gross margin, cost reductions in G&A, and disciplined liquidity position are notable positives. However, sizable non-cash goodwill and deferred tax charges materially impacted reported earnings, adjusted operating margins declined, recruiting and leadership development remain weak, and the India launch was delayed. Near-term FX headwinds and modest operating cash flow further temper the outlook. On balance, the company shows encouraging strategic traction and product adoption but faces meaningful near-term financial and operational headwinds.
Q2-2026 Updates
Positive Updates
Negative Updates
Company Guidance
Nu Skin updated Q3 revenue guidance to $310–$340 million (with an expected 2–3% foreign currency headwind) and Q3 EPS of $0.00–$0.09 reported (adjusted $0.10–$0.20), and revised full‑year revenue to $1.28–$1.35 billion (≈1% FX headwind) with reported FY EPS of −$4.90 to −$4.73 (adjusted $0.70–$0.90) and an adjusted effective tax rate of ~35%; management expects to place 50,000–60,000 Prysm iO devices by year‑end (vs. >39,000 placed to date, up ~30% QoQ, and 2.5 million scans, up ~25% QoQ). The company plans $5–$10 million of cash‑based organizational transition costs through year‑end excluded from adjusted results and also excluded the Q2 non‑cash charges (a $78.9M goodwill impairment and a $167.5M deferred tax valuation allowance) from adjusted guidance; for context Q2 revenue was $320.1M, gross margin 68.2% (core 77.7%), adjusted operating margin 6.1%, cash $189.6M, debt $213.7M and Q2 operating cash flow $10.6M.
Nu Skin Financial Statement Overview
Summary
Nu Skin's financial performance is burdened by a severe revenue contraction to $1.37 billion (TTM) and steep net losses resulting in a -15.7% profit margin. While management has successfully deleveraged the balance sheet to a healthy debt-to-equity ratio of 0.48, free cash flow has plummeted to just $10.7 million, severely limiting financial flexibility.
Income Statement
35NegativeBalance Sheet
55NeutralCash Flow
45Neutral| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.38B | 1.49B | 1.73B | 1.97B | 2.23B | 2.70B |
| Gross Profit | 951.49M | 1.03B | 1.18B | 1.36B | 1.59B | 2.02B |
| EBITDA | 39.32M | 262.41M | -78.83M | 204.68M | 174.97M | 319.78M |
| Net Income | -216.39M | 160.20M | -146.59M | 8.60M | 104.78M | 147.27M |
Balance Sheet | ||||||
| Total Assets | 1.12B | 1.41B | 1.47B | 1.81B | 1.82B | 1.91B |
| Cash, Cash Equivalents and Short-Term Investments | 189.64M | 239.84M | 197.99M | 267.82M | 278.51M | 354.81M |
| Total Debt | 263.74M | 364.25M | 478.23M | 607.33M | 520.52M | 503.79M |
| Total Liabilities | 578.79M | 600.07M | 817.46M | 984.50M | 923.67M | 993.71M |
| Stockholders Equity | 542.74M | 805.24M | 651.46M | 821.97M | 897.30M | 912.77M |
Cash Flow | ||||||
| Free Cash Flow | 10.78M | 46.01M | 70.16M | 60.15M | 49.01M | 72.97M |
| Operating Cash Flow | 50.81M | 80.29M | 111.74M | 118.64M | 108.06M | 141.58M |
| Investing Cash Flow | -39.60M | 170.66M | -37.96M | -134.50M | -67.08M | -88.73M |
| Financing Cash Flow | -79.16M | -202.40M | -133.18M | 10.73M | -99.50M | -104.70M |
Nu Skin Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NUS, the sentiment is Negative. The current price of 4.65 is below the 20-day moving average (MA) of 4.85, below the 50-day MA of 4.76, and below the 200-day MA of 6.28, indicating a bearish trend. The MACD of -0.02 indicates Positive momentum. The RSI at 43.27 is Neutral, neither overbought nor oversold. The STOCH value of 14.19 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for NUS.
Nu Skin Risk Analysis
Nu Skin disclosed 12 risk factors in its most recent earnings report. Nu Skin reported the most risks in the "Legal & Regulatory" category.
Latest Risks Added
1 New RiskNu Skin Peers Comparison
Overall Rating
HNST71Outperform
ELF65Neutral
EL58Neutral
YSG49Neutral
ODD48Neutral
NUS43Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 71Outperform | $447.38M | -40.25 | -6.99% | ― | -12.26% | -282.39% | |
| 65Neutral | $6.59B | 111.54 | 5.18% | ― | 31.23% | -42.14% | |
| Sector * | 62Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% |
| 58Neutral | $39.58B | 214.18 | 4.63% | 1.28% | 5.51% | ― | |
| 49Neutral | $211.05M | -6.90 | -7.20% | ― | 25.10% | 59.14% | |
| 48Neutral | $999.52M | 72.23 | 4.60% | ― | -9.68% | -84.42% | |
| 43Neutral | $226.35M | -1.04 | -29.42% | 5.16% | -15.44% | -319.79% |
* Consumer Defensive Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| NUS | Nu Skin Enterprises | 4.65 | -5.68 | -54.97% | |
| EL | Estée Lauder | 109.23 | 17.29 | 18.80% | |
| ELF | e.l.f. Beauty, Inc. | 111.69 | -9.25 | -7.65% | |
| YSG | Yatsen Holding Ltd. | 2.25 | -4.17 | -64.95% | |
| HNST | Honest Company, Inc. | 4.17 | 0.81 | 24.11% | |
| ODD | ODDITY Tech Ltd. Class A | 21.67 | -22.21 | -50.62% |
Nu Skin Corporate Events
Nu Skin Announces EVP Medical Leave and Sales Oversight
NeutralOn Aug. 17, 2026, Nu Skin Enterprises, Inc. announced that Executive Vice President and President of Global Sales Justin Keisel began a medical leave of absence. Executive Vice President, Chief Operating Officer and Chief Legal Officer Chayce Clark w...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Aug 11, 2026